Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia | Zendy

Meletios Α. Dimopoulos | Zendy; Alessandra Tedeschi | Zendy; Judith Trotman | Zendy; Ramón GarcíaSánz | Zendy; D. Blair Macdonald | Zendy; Véronique Leblond | Zendy; Beatrice Mahé | Zendy; Charles Herbaux | Zendy; Constantine S. Tam | Zendy; Lorella Orsucci | Zendy; M. Lia Palomba | Zendy; Jeffrey Matous | Zendy; Chaim Shustik | Zendy; Efstathios Kastritis | Zendy; Steven P. Treon | Zendy; Jianling Li | Zendy; Zeena Salman | Zendy; Thorsten Graef | Zendy; Christian Buske | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Author(s) -

Meletios Α. Dimopoulos,

Alessandra Tedeschi,

Judith Trotman,

Ramón GarcíaSánz,

D. Blair Macdonald,

Véronique Leblond,

Beatrice Mahé,

Charles Herbaux,

Constantine S. Tam,

Lorella Orsucci,

M. Lia Palomba,

Jeffrey Matous,

Chaim Shustik,

Efstathios Kastritis,

Steven P. Treon,

Jianling Li,

Zeena Salman,

Thorsten Graef,

Christian Buske

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1802917

Subject(s) - rituximab , ibrutinib , medicine , waldenstrom macroglobulinemia , placebo , macroglobulinemia , oncology , gastroenterology , lymphoma , chronic lymphocytic leukemia , leukemia , multiple myeloma , pathology , alternative medicine

Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab in patients with this disease, both in those who had not received previous treatment and in those with disease recurrence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research